Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.